XTR004 PET heart scan to detect flow‑limiting coronary blockages

Evaluation of the Efficacy and Safety of XTR004 Injection in Detecting Blood Flow Restrictive Stenosis in Patients With Suspected or Known Stable Coronary Artery Disease: A Multicenter, Open-Label, Phase III Clinical Trial

This trial tests whether XTR004 PET heart scans can accurately detect significant coronary artery blockages in adults with suspected or known coronary artery disease compared with QCA and FFR.

Quick facts

• Phase: Phase 3
• Study type: Interventional
• Enrollment: 395 (estimated)
• Ages: 18 Years to 80 Years
• Sex: All
• Sponsor: Sinotau Pharmaceutical Group (Industry-sponsored)
• Drugs / interventions: radiation
• Locations: 5 sites (Beijing and 4 other locations)
• Trial ID: NCT07439133 on ClinicalTrials.gov

What this trial studies

This is a Phase 3 interventional diagnostic study comparing visual readings of XTR004 PET myocardial perfusion imaging (MPI) against a composite reference standard of quantitative coronary angiography (QCA) and fractional flow reserve (FFR) for detecting restrictive coronary stenoses. Adults aged 18–80 with suspected or confirmed stable coronary artery disease and relevant risk factors are enrolled and undergo XTR004 PET imaging plus invasive angiography/FFR. The primary outcome is diagnostic accuracy of visual PET interpretation for identifying flow‑limiting lesions. The trial is conducted at several major Beijing hospitals and sponsored by Sinotau Pharmaceutical Group.

Who should consider this trial

Good fit: Adults 18–80 with suspected or confirmed stable coronary artery disease who meet the listed risk‑factor criteria and can give informed consent are the intended participants.

Not a fit: Patients with severe unstable cardiac conditions, uncontrolled hypertension, hypotension, or other exclusionary comorbidities are unlikely to be eligible or to benefit from participation.

Why it matters

Potential benefit: If successful, XTR004 PET could provide a noninvasive, accurate way to identify flow‑limiting coronary stenoses and help guide treatment decisions.

How similar studies have performed: Other PET myocardial perfusion approaches (e.g., rubidium‑82 or N‑13 ammonia PET) have shown good concordance with FFR for detecting ischemia, but XTR004 is a novel agent that requires phase 3 validation.

Eligibility criteria

Inclusion Criteria:

* Participants aged 18 to 80 years, male or female.
* Suspected or confirmed patients with stable coronary heart disease. Those suspected of having stable coronary heart disease must meet at least one of the following risk factors: hypertension, hyperlipidemia, diabetes, obesity (BMI ≥28), a history of alcohol abuse, a smoking history, a family history of coronary heart disease, postmenopausal status, or age 60 years or older.
* Participants can communicate well with investigators, understand and comply with clinical trial requirements, voluntarily participate in the study, and sign an informed consent form.

Exclusion Criteria:

* Participants with severe cardiovascular diseases, including but not limited to unstable angina (Canadian Cardiac Society (CCS) Grade III/IV angina pectoris), uncontrolled hypertension (systolic blood pressure ≥ 180 mmHg and/or diastolic ≥110 mmHg despite long-term regular antihypertensive medication), hypotension (resting systolic blood pressure \<90 mmHg), acute myocardial infarction, second or third-degree atrioventricular block, sinoatrial node disease, NYHA Class III/IV heart failure, dilated or hypertrophic cardiomyopathy, pericarditis, valvular heart disease, aortic dissection, uncontrolled severe arrhythmias, congenital heart disease, those who have undergone coronary artery bypass grafting or interventional procedures within three months, and those determined unsuitable for participation in this study by investigators;
* Participants with severe acute or chronic pulmonary diseases (including but not limited to COPD, asthma, bronchiectasis, emphysema, pulmonary fibrosis, pulmonary embolism, pneumonia, etc.) who are determined unsuitable for participation by the investigator;
* Participants with severe or unstable central nervous system disorders (including but not limited to unstable cerebrovascular diseases, active epilepsy, CNS infections, CNS diseases accompanied by mental disorders or motor impairments) who are determined unsuitable for participation by the investigator;
* Participants with severe bleeding disorders or coagulation dysfunction (including but not limited to purpura, hemophilia, vitamin K deficiency, etc.) who are determined unsuitable for participation by the investigator;
* Participants with severe liver dysfunction (including but not limited to viral hepatitis, autoimmune hepatitis, cirrhosis, liver cancer, etc.) who are determined unsuitable for participation by the investigator;
* Participants with severe kidney impairment (including but not limited to glomerulonephritis, renal insufficiency, nephrotic syndrome, membranous nephropathy, hydronephrosis, renal cystopathy, etc.) who are determined unsuitable for participation by the investigator;
* Participants with fever or active infectious diseases who are determined unsuitable for participation by the investigator;
* Participants with known alcohol allergy who are determined unsuitable for participation by the investigator;
* participants with known adenosine allergy who are determined unsuitable for participation by the investigator;
* Participants with known iodine contrast agent allergy who are determined unsuitable for participation by the investigator;
* Within the past 10 years, significant occupational exposure to ionizing radiation (e.g., exceeding 50 mSv/year) or exposure to radioactive substances or ionizing radiation for therapeutic/research purposes;
* Male or women of childbearing age not using effective contraception during study participation and within 6 months post-study (effective contraception refers to sterilization, intrauterine device, condoms, abstinence, or surgical blockage of vas deferens/fallopian tubes);
* Female participants in pregnancy or lactation
* Individuals with claustrophobia, bipolar disorder, mental disorders, or poor compliance;
* Participation in other investigational drug trials within 30 days prior to enrollment or planned during study;
* Any other circumstances determined unsuitable by investigators.

Where this trial is running

Beijing and 4 other locations

• Beijing Anzhen Hospital, Capital Medical University — Beijing, China (Recruiting)
• Beijing Tongren Hospital — Beijing, China (Recruiting)
• Peking Union Medical College Hospital — Beijing, China (Recruiting)
• The First People's Hospital of Foshan — Foshan, China (Recruiting)
• TEDA International Cardiovascular Hospital — Tianjin, China (Recruiting)

Study contacts

• Study coordinator: Ling Yuan

Conditions Coronary Artery Disease